Vertex secured a Germany reimbursement agreement for CASGEVY and signed a WuXi Biologics pact for a preclinical autoimmune T-cell engager. The moves add to efforts to build revenue beyond cystic fibrosis.
Cynata raised $1.5 million through a placement at $0.25 a share ahead of Phase 3 osteoarthritis and Phase 2 aGvHD trial readouts due in May and June 2026. Its aGvHD study has completed the 100-day primary evaluation period for all 65 participants.
A longitudinal study of 460,000 teenagers found adolescent cannabis use was linked to higher risks of later bipolar, psychotic, anxiety and depression diagnoses. Separate research and expert guidance say THC effects, especially long term, still need more study.
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
Biopharma companies face a $275b patent cliff as licensing activity shifts toward China. China represented almost half of 2025 licensing activity and contributes about 30% of the global biotech pipeline.
China’s cross-border biotech outlicensing hit US$60 billion in the first quarter of 2026. AbbVie’s up to $745 million Haisco pain deal highlights multinationals’ rising interest in Chinese drug assets.
Phase 3 PSMAddition showed that adding 177Lu-PSMA-617 to ADT plus an ARPI improved radiographic progression-free survival in PSMA-positive mHSPC. Health-related quality of life and pain were largely maintained.
Clinical trials show psychedelic substances like psilocybin, LSD and MDMA combined with therapy can effectively treat depression, anxiety and addiction. Several substances are in Phase III trials, with esketamine already approved for treatment-resistant depression. Research suggests these treatments may work with fewer doses than traditional medications.
The FDA has authorized the first human trial of an allogeneic stem cell therapy for epilepsy, developed by Shanghai-based Unixell Biotechnology. The therapy uses donor-derived stem cells to produce GABA and suppress seizures in drug-resistant patients.
Xenon Pharmaceuticals will announce topline data from its Phase 3 X-TOLE2 study of azetukalner in patients with focal onset seizures on March 9, 2026, during a conference call at 8:00 a.m. ET.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07601945 |
External Oblique Intercostal Fascial Plane Block Versus Rectus Sheath Block for Postoperative Analgesia |
COMPLETED | PHASE3 |
| NCT07600814 |
Pain Induced by m-Cresol as Preservative |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07599826 |
Active vs. Passive VR During Office-based ENT Procedures |
NOT_YET_RECRUITING | NA |
| NCT07599514 |
Efficacy of an Experimental Gel Based on Libidibia Ferrea on Post-bleaching Tooth Sensitivity |
NOT_YET_RECRUITING | NA |
| NCT07590869 |
Using a Stress Ball With Music During Colonoscopy |
COMPLETED | NA |
| NCT07581080 |
Biofield Therapy for the Support of Immunotherapy-related Symptoms Among Adult Cancer Patients - A Pilot Study |
RECRUITING | NA |
| NCT07579039 |
Combined Effect of Prenatal Stretching and Kinesiotaping in Pregnant Women With Low Back Pain |
RECRUITING | NA |
| NCT07576582 |
Peloid Therapy in Temporomandibular Joint Dysfunction |
RECRUITING | NA |
| NCT07575542 |
The Effects of Spinal Mobilization Added to an Exercise Program in Recreational Tennis Players With Mechanical |
COMPLETED | NA |
| NCT07571772 |
The Effect of Hot Compress in Patients With Knee Osteoarthritis |
COMPLETED | NA |
